Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2014

01-04-2014 | Editorial Commentary

The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE)

Authors: Carlo Spreafico, Marco Maccauro, Vincenzo Mazzaferro, Carlo Chiesa

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2014

Login to get access

Excerpt

Transarterial radioembolization (TARE) with 90Y microspheres is a very promising treatment modality in inoperable primary liver malignancies (mainly hepatocellular carcinoma, HCC), as well as in secondary liver lesions (mainly colorectal metastases), with some interesting results in other less diffused malignancies such as intrahepatic cholangiocarcinoma and neuroendocrine metastases. However, TARE is not yet included in liver management guidelines, since it has been introduced into clinical practice only recently, randomized studies demonstrating better outcomes with respect to consolidated standard of care have not yet been performed. Two kinds of 90Y-loaded microspheres are available, as we discuss in detail in the following sections. …
Literature
1.
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.
2.
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38.PubMedCrossRef
3.
Llovet JM, Sergio R, Mazzaferro V, Hilgard P, Gane E, Blanc J-F. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef
4.
Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of Sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.PubMedCrossRef
5.
Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.PubMedCrossRef
6.
Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84(5):311–8.PubMedCrossRef
7.
Hilgard P, Hamami M, El Fouly A, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1751–49.CrossRef
8.
Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78.PubMedCrossRef
9.
Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology. 2013;57(5):1826–37.PubMedCrossRef
10.
Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057–68.PubMedCentralPubMedCrossRef
11.
Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons. Curr Challenges Clin Perspect Hepatol. 2013;2013(58):2188–97.
12.
Rosenbaum CE, Verkooijen HM, Lam MG, Smits ML, Koopman M, van Seeters T, et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med. 2013;54(11):1890. doi:10.​2967/​jnumed.​113.​119545.PubMedCrossRef
13.
Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.PubMedCrossRef
14.
Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94.PubMedCrossRef
15.
Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16:937–45.PubMedCrossRef
16.
Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guidelines for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406.PubMedCrossRef
17.
Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. Vasc Interv Radiol. 2006;17:1251–78.CrossRef
18.
Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med. 2014;55:135–40.PubMedCrossRef
19.
Chiesa C, Mira M, Maccauro M, Romito R, Spreafico C, Sposito S, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging. 2012;56:503–8.PubMed
20.
Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y SIR spheres: radiobiological considerations. J Nucl Med. 2010;51:1377–85.PubMedCrossRef
21.
Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D, et al. Radioembolization with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging. 2008;35(11):2088–96.PubMedCrossRef
22.
Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Questa A, Viudez A, et al. Liver disease induced by radioembolization of liver tumours. Cancer. 2008;112(7):1539–46.CrossRef
23.
Lau WY, Kennedy A, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82(1):401–7.PubMedCrossRef
24.
Rhee TK, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247(6):1029–35.PubMedCrossRef
25.
Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168–97.PubMed
26.
Lewandowski RJ, Minocha J, Memon K, Riaz A, Gates VL, Ryu RK, et al. Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. Eur J Nucl Med Mol Imaging. 2013. doi:10.​1007/​s00259-013-2575-8.
27.
Lewandowski RJ, Riaz A, Yu R, et al. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: result from a pilot study. J Vasc Interv Radiol. 2009;20:1023–33.CrossRef
28.
Nijsen JF, Smits ML, van het Ship AD, Lam MG, van den Bosch MA, Elshot M, et al. Radioactive holmium loaded poly(L-lactic acid) microspheres for treatment of liver malignancies: results of a phase I, dose escalation study in patients: the HEPAR trials. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2:Abstract OP469.
29.
Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, et al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol. 2011;2011:571261.PubMedCentralPubMed
30.
Bilbao JI, de Martino A, de Luis E, Díaz-Dorronsoro L, Alonso-Burgos A, Martínez de la Cuesta A, et al. Biocompatibility, inflammatory response, and recanalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol. 2009;32:727–36.PubMedCentralPubMedCrossRef
31.
Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med. 2005;46:99S–106.PubMed
Metadata
Title
The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE)
Authors
Carlo Spreafico
Marco Maccauro
Vincenzo Mazzaferro
Carlo Chiesa
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2674-6

Other articles of this Issue 4/2014

European Journal of Nuclear Medicine and Molecular Imaging 4/2014 Go to the issue

Book Review

John Tsiouris, Pina C. Sanelli, Joseph P. Comunale: Case-Based Brain Imaging, 2nd Edition

Original Article

18F-FDG PET/CT impact on testicular tumours clinical management

Original Article

Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients

Original Article

Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study

Original Article

Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET

Original Article

Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection